Erik Gatenholm
Born 1989. CEO since 2016.
Education and work experience:
B.Sc. at Virginia Tech University and a M.Sc. in Innovation & Industrial Management from Gothenburg University. Erik has documented success in biotechnology entrepreneurship with more than 13 years of entrepreneurial experience. Honors include: Forbes 30 Under 30, MIT Review 35 Under 35, and Entrepreneur of the year 2020.
Other board assignments:
Board member of BICO Group AB and chairman of BICO International AB
Shareholding in BICO:
A-shares: 848,958, B-shares: 8,767,036. Ownership: 15%, voting right: 22.24%
Jacob Thordenberg
Chief Financial Officer
Born 1985, CFO since 2023.
Education:
M.Sc Corporate and financial management from Lund University, Sweden.
Work experience:
Over 10 years of financial experience, including Head of M&A at BICO, M&A Director at Telia Company and Deloitte Transaction Services
Other board assignments:
None
Shareholdings in BICO:
900 B shares. 12000 options (LTIP 2021)
Dr. Héctor Martinez
EVP, CTO & Co-founder
Born 1985. CTO since 2016.
Education and work experience:
M.Sc. and PhD in Biomedical Engineering from Chalmers University of Technology. Hector has over 10 years of experience in developing and commercializing cutting-edge converging technologies that enable our customers to create, understand and master biology.
Other board assignments:
Board member of BICO International AB
Shareholding in BICO:
A-shares: 567,709, B-shares: 5,751,695. Ownership: 9.73%, voting right: 14.62%
Marius Balger
Chief Operating Officer
Born 1968, COO since March 2023
Education:
Master of Science in General Mechanical Engineering (Diplom-Ingenieur) Technical University Darmstadt – Hesse, Germany
Work experience:
27 years of general business management experience and 21 Years in Life Science and IVD. Including cross-functional responsibilities ranging from operations, through building and leading sales and distribution networks, product development, lean manufacturing to after-sale service. Key leadership functions filled in the past such as: General Manager and VP Asia Pacific at MAN AG, CEO of a midsize CDMO and Senior Vice President Partnering Business at Tecan AG
Other board assignments:
Currently none, Advisory function at Kilobaser GmbH and AmplifiDx, Inc
Artur Aira
Born 1967. Head of Corporate Development & M&A since March 2023.
Education and work experience:
Medtech Eng., and MBA, Chalmers. More than 25 years’ experience in Life Science (biotech, Pharma, Diagnostics). Former CEO of Organon, bioMerieux Nordics, Ad-dtech Life Lifescience, Addlife dvlp, COO and Exec VP Addlife and Abigo Medical AB.
Other board assignments:
Has Board member experience of more than 35 companies. Board member of Integrum and Predicare. Board member of CELLINK 2017-2020.
Shareholding in BICO:
B-shares: 80,000
Options: 40,000
Lotta Bus
Born 1970. General Counsel since 2020.
Education and work experience:
LL.M. University of Lund & Maastricht. Over 20 years of experience as an attorney working for the law firms Vinge, MAQS and Magnusson including 14 years of experience of management as partner and five years as CEO.
Other board assignments:
Board member of Sincrly AB and BICO International AB.
Shareholding in BICO:
B-shares: 7,000
Dr. Holger Eickhoff
SVP & Business Area Director
Born 1965. Business Area Director Bioautomation since 2020. CEO SCIENION since 2001.
Education and work experience:
Diploma in Chemistry Heidelberg University. PhD in Biology University Jena. Post Doc at Max Planck for Molecular Genetics. Founder SCIENION.
Other board assignments: –
Shareholding in BICO:
B-shares: 251,660, Ownership: 0.40%, voting right: 0.33%
Dr. Jonas Schöndube
SVP & Business Area Director
Born 1985. Business Area Director Biosciences since 2020.
Education and work experience:
M.Sc. in Micro and Nanosystems from ETH Zurich. PhD in Engineering from University of Freiburg. Founder and CEO (2014 – May 2021) of CYTENA.
Other board assignments:
Board member CYTENA Bioprocess Solutions co. Ltd., Taiwan.
Shareholding in BICO:
B-shares: 218,168, options: 60,000. Ownership: 0.38%, voting right: 0.31%
Erik Gatenholm
CEO, Co-founder
Born 1989. CEO since 2016.
Education and work experience:
B.Sc. at Virginia Tech University and a M.Sc. in Innovation & Industrial Management from Gothenburg University. Erik has documented success in biotechnology entrepreneurship with more than 13 years of entrepreneurial experience. Honors include: Forbes 30 Under 30, MIT Review 35 Under 35, and Entrepreneur of the year 2020.
Other board assignments:
Board member of BICO Group AB and chairman of CELLINK Options AB.
Shareholding in BICO:
A-shares: 848,958, B-shares: 8,754,236. Ownership: 14.98%, voting right: 22.23%
Dr. Héctor Martinez
EVP, CTO and Co-founder
Education and work experience:
M.Sc. and PhD in Biomedical Engineering from Chalmers University of Technology. Hector has over 10 years of experience in developing and commercializing cutting-edge converging technologies that enable our customers to create, understand and master biology.
Other board assignments:
Board member of CELLINK Options AB.
Shareholding in BICO:
A-shares: 567,709, B-shares: 5,751,695. Ownership: 9.73%, voting right: 14.62%
Artur Aira
SVP and Business Area Director
Born 1967. Business Area Director Bioprinting since 2020.
Education and work experience:
Medtech Eng., and MBA, Chalmers. More than 25 years’ experience in Life Science (biotech, Pharma, Diagnostics). Former CEO of Organon, bioMerieux Nordics, Ad-dtech Life Lifescience, Addlife dvlp, COO and Exec VP Addlife and Abigo Medical AB.
Other board assignments:
Has Board member experience of more than 35 companies. Board member of Integrum and Predicare. Board member of CELLINK 2017-2020.
Shareholding in BICO:
B-shares: 80,000
Options: 40,000
Erica Bell
SVP and Chief People Officer
Born 1973. Chief People Officer since 2021.
Born 1973. Chief People Officer since 2021.
Education and work experience:
MA, Management from Cambridge College 25 years of HR experience working for large organizations to include GE. Held various HR leadership roles across multiple industries to include 13 years in Healthcare, Medical Device and Life Sciences. Extensive experience in integration & acquisitions, change management and international HR. Proven ability in creating global organizations as well as developing and integrating corporate cultures. View HR as a strategic partner critical to the fulfillment of the corporate mission & vision.
Other board assignments:
Board assignments – none
Non board assignments – Advisor/Consultant Weavr Health
Shareholding in BICO:
–
Lotta Bus
SVP and General Counsel
Born 1970. General Counsel since 2020.
Born 1970. General Counsel since 2020.
Education and work experience:
LL.M. University of Lund & Maastricht. Over 20 years of experience as an attorney working for the law firms Vinge, MAQS and Magnusson including 14 years of experience of management as partner and five years as CEO.
Other board assignments:
Board member of Sincrly AB.
Shareholding in BICO:
B-shares: 7,000
Dr. Jonas Schöndube,
SVP and Business Area Director
Born 1985. Business Area Director Biosciences since 2020.
Born 1985. Business Area Director Biosciences since 2020.
Education and work experience:
M.Sc. in Micro and Nanosystems from ETH Zurich. PhD in Engineering from University of Freiburg. Founder and CEO (2014 – May 2021) of CYTENA.
Other board assignments:
Board member CYTENA Bioprocess Solutions co. Ltd., Taiwan.
Shareholding in BICO:
B-shares: 218,168, options: 60,000. Ownership: 0.38%, voting right: 0.31%
Dr. Holger Eickhoff
SVP and Business Area Director
Born 1965. Business Area Director Bioautomation since 2020. CEO SCIENION since 2001.
Born 1965. Business Area Director Bioautomation since 2020. CEO SCIENION since 2001.
Education and work experience:
Diploma in Chemistry Heidelberg University. PhD in Biology University Jena. Post Doc at Max Planck for Molecular Genetics. Founder SCIENION.
Other board assignments: –
Shareholding in BICO:
B-shares: 251,660, Ownership: 0.40%, voting right: 0.33%
Interim Chief Financial Officer
Born 1977. Interim Chief Financial Officer since 2022.
Born 1977. Interim Chief Financial Officer since 2022.
Education and work experience:
M.Sc. in Business Administration from University of Gothenburg. Over 20 years of financial experience including CFO in Vitrolife AB (publ) 2011-2021.
Other board assignments:
CEO and Board member of Engblom Advisory AB
Shareholding in BICO:
B-shares: 5,000
Born 1975. SVP Investor Relations since 2022.
Born 1975. SVP Investor Relations since 2022.
Education and work experience:
Business Economy, IHM Business School, Strategic Brand Management IHM Business School. Over 15 years of communication and investor relation experience including Head of Investor Relations Catena Media 2018 – 2021 and CCO & IR Collector Bank 2016 – 2017.
Other board assignments:
Senior Advisor Investor Relations & Communications NFT Ventures AB.
Shareholding in BICO:
Options: 24,000
B-shares: 10,771 of which 5,300 are owned through close relatives.
